Ascentage Pharma Group International ((HK:6855)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Study Overview: Ascentage Pharma Group International is conducting a pivotal Phase 3 study titled ‘A Pivotal Registrational Phase 3 Study of Olverembatinib Combined With Chemotherapy Versus Imatinib Combined With Chemotherapy in Patients With Newly Diagnosed Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL)’. The study aims to evaluate the efficacy and safety of Olverembatinib, a promising treatment for Ph+ALL, compared to the established drug Imatinib, both in combination with chemotherapy.
Intervention/Treatment: The study tests two treatments: Olverembatinib, an experimental drug administered orally every other day, and Imatinib, an active comparator given once daily. Both are combined with chemotherapy to treat newly diagnosed Ph+ALL patients.
Study Design: This global, multicenter study is interventional and randomized, with a parallel assignment model. It is open-label, meaning no masking is involved, and its primary purpose is treatment-focused, aiming to establish the best therapeutic approach for Ph+ALL.
Study Timeline: The study began on September 4, 2023, and is currently recruiting participants. The last update was submitted on November 5, 2024. These dates are crucial for tracking the study’s progress and anticipating its impact on the market.
Market Implications: The outcome of this study could significantly influence Ascentage Pharma’s stock performance, as successful results may enhance investor confidence and market position. The study’s progress is closely watched by competitors and investors, given the competitive landscape of leukemia treatments.
The study is ongoing, with further details available on the ClinicalTrials portal.